FI92716B - Nya monoklonala antikroppar för IFN-omega, deras framställningsförfaranden och deras användning för rening och påvisning av IFN-omega - Google Patents
Nya monoklonala antikroppar för IFN-omega, deras framställningsförfaranden och deras användning för rening och påvisning av IFN-omega Download PDFInfo
- Publication number
- FI92716B FI92716B FI874273A FI874273A FI92716B FI 92716 B FI92716 B FI 92716B FI 874273 A FI874273 A FI 874273A FI 874273 A FI874273 A FI 874273A FI 92716 B FI92716 B FI 92716B
- Authority
- FI
- Finland
- Prior art keywords
- ifn
- omega
- antibody
- omg
- monoclonal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 26
- 238000001514 detection method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 9
- 238000000746 purification Methods 0.000 title claims description 9
- 108010050904 Interferons Proteins 0.000 claims abstract description 29
- 102000014150 Interferons Human genes 0.000 claims abstract description 29
- 229940079322 interferon Drugs 0.000 claims abstract description 22
- 229940047124 interferons Drugs 0.000 claims abstract description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 11
- 238000003018 immunoassay Methods 0.000 claims description 7
- 108010047761 Interferon-alpha Proteins 0.000 claims description 6
- 102000006992 Interferon-alpha Human genes 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000013198 immunometric assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Hybridomacellinjer, med benämningen OMG-4 (deponerad med ECACC-nummer 87081401), OMG-5 (deponerad med ECACC-nummer 87081402) och OMG-7 (deponerad med ECACC-nummer 87081403).
2. Monoklonala antikroppar av IgG-typ, känneteck-n a d e därav, att dessa neutraliserar omega-interferons aktivitet, men inte INF-S:s, IFN-yrs eller a-interferons aktivitet, och de bildas genom att odla hybridomacellinjer enligt patentkravet 1.
3. Monoklonala antikroppar enligt patentkravet 2, kanne -tecknade därav, att dessa är bildade av klonerna OMG-4, OMG-5 och OMG-7, som är deponerade med ECACC-nummer 87081401, 87081402 och 87081403, och att de i en koncentration av 100 μg/ml neutraliserar IFN-omegal:s aktivitet, men inte INF-a2c:s, IFN-S:s eller IFN-yis aktivitet.
4. Monoklonala antikroppar enligt patentkraven 2 eller 3, kännetecknade därav, att de är markerade.
5. Förfarande för framställning av monoklonala antikroppar enligt patentkraven 2-4, kännetecknat därav, att efter tillväxten av hybridomacellinjerna enligt patentkravet 1 separeras de anti-omega-interferon-specifikä IgG-anti-kropparna och den sä erhällna monoklonala antikropparna even-tuellt förenas med en markering.
6. Användningen av nya monoklonala antikroppar enligt patentkravet 2 eller 3 för rengörning av omega-interferon.
7. En för rengörning av omega-interferon lämplig antikropp-affinitetbärare, kännetecknad därav, en mono-klonal antikropp enligt patentkraven 2 eller 3 bindes kovalent vid en lämplig aktiverad bärare. 9271 6
8. Förafrande för framställning av en antikropp-affinitet-bärare enligt patentkravet 7, kännetecknat därav, att en monoklonal antikropp enligt patentkravet 2 eller 3 bindes kovalent vid en lämplig aktiverad bärare.
9. Förfarande för framställning av omega-interferon, kännetecknat därav, att IFN-omega bindes vid en antikropp-af finitet-bärare enligt patentkravet 7 och därefter elueras pä nytt.
10. Användningen av nya monoklonala antikroppar enligt patent-kraven 2 eller 3 eller deras markerade derivat enligt patentkravet 6 för detektering av IFN-omega.
11. Kitt lämpligt för detektering av IFN-omega, k ä n n e -t e c k n a t därav, att det innehäller en monoklonal antikropp enligt patentkraven 2-4.
12. Förfarande för pävisning av INF-omega, kännetecknat därav, att provet inkuberas med en antikropp enligt patentkravet 4 och antikroppens reaktion med IFN-omega regist-reras.
13. Kitt lämpligt för att pävisa eller kvantitativt bestämma IFN-omega, kännetecknat därav, att detta innehäller en fast fas, vid vilken a) en monoklonal eller polyklonal antikropp mot IFN-omega är fäst och b) den bildade binära komplexen bestäms med hjälp av den monoklonala antikroppen enligt patentkravet 4.
14. Förfarande för att pävisa eller kvantitativt bestämma IFN-omega, kännetecknat därav, att provet a) inkuberas med en monoklonal eller polyklonal antikropp mot IFN-omega, vilken är bunden vid en bärare, b) tili ett sä erhället prov sätts en antikropp enligt patentkravet 4 och K 9271 6 c) koncentrationen pä den sä erhällna antikroppen enligt patentkravet 4 bestäms.
15. Immunbestämningsförfarande enligt patentkravet 11 eller 13, kännetecknat därav, att detta identifierar endast IFN-omega, men inte interferoner av a-, β- eller γ-typ. i ·
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863633323 DE3633323A1 (de) | 1986-10-01 | 1986-10-01 | Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega |
| DE3633323 | 1986-10-01 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI874273A0 FI874273A0 (sv) | 1987-09-30 |
| FI874273A FI874273A (sv) | 1988-04-02 |
| FI92716B true FI92716B (sv) | 1994-09-15 |
| FI92716C FI92716C (sv) | 1994-12-27 |
Family
ID=6310754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI874273A FI92716C (sv) | 1986-10-01 | 1987-09-30 | Nya monoklonala antikroppar för IFN-omega, deras framställningsförfaranden och deras användning för rening och påvisning av IFN-omega |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5317089A (sv) |
| EP (1) | EP0262571B1 (sv) |
| JP (1) | JP2622260B2 (sv) |
| KR (1) | KR960009724B1 (sv) |
| AT (1) | ATE83262T1 (sv) |
| AU (1) | AU616158B2 (sv) |
| CA (1) | CA1320160C (sv) |
| DD (1) | DD269165A5 (sv) |
| DE (2) | DE3633323A1 (sv) |
| DK (1) | DK172801B1 (sv) |
| ES (1) | ES2052534T3 (sv) |
| FI (1) | FI92716C (sv) |
| GR (1) | GR3006846T3 (sv) |
| HU (1) | HUT45092A (sv) |
| IE (1) | IE59836B1 (sv) |
| IL (1) | IL84040A (sv) |
| NO (1) | NO173831C (sv) |
| NZ (1) | NZ222006A (sv) |
| PH (1) | PH30662A (sv) |
| PT (1) | PT85830B (sv) |
| SU (1) | SU1602393A3 (sv) |
| ZA (1) | ZA877354B (sv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0310940B1 (en) * | 1987-09-30 | 1994-11-23 | Fujirebio Kabushiki Kaisha | Analytical element for enzyme immunoassays |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
| JP2008505619A (ja) * | 2004-06-16 | 2008-02-28 | ヴェレニウム コーポレイション | 葉緑素を酵素的に脱色するための組成物及び方法 |
| EP2536435B1 (en) * | 2010-02-18 | 2017-11-15 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
| EP2970461A4 (en) * | 2013-03-15 | 2016-11-23 | Janssen Biotech Inc | INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI77877C (sv) * | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Förfarande för framställning och rening av human Le-formig interferonp rotein. |
| DE3306060A1 (de) * | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0170204B1 (de) * | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| EP0174143B1 (en) * | 1984-08-27 | 1989-11-08 | Genentech, Inc. | Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor |
| DE3607835A1 (de) * | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
-
1986
- 1986-10-01 DE DE19863633323 patent/DE3633323A1/de not_active Withdrawn
-
1987
- 1987-09-23 ES ES87113896T patent/ES2052534T3/es not_active Expired - Lifetime
- 1987-09-23 EP EP87113896A patent/EP0262571B1/de not_active Expired - Lifetime
- 1987-09-23 DE DE8787113896T patent/DE3783002D1/de not_active Expired - Lifetime
- 1987-09-23 AT AT87113896T patent/ATE83262T1/de not_active IP Right Cessation
- 1987-09-28 US US07/102,160 patent/US5317089A/en not_active Expired - Lifetime
- 1987-09-29 SU SU874203388A patent/SU1602393A3/ru active
- 1987-09-29 DD DD30737687A patent/DD269165A5/de unknown
- 1987-09-30 NO NO874107A patent/NO173831C/no unknown
- 1987-09-30 NZ NZ222006A patent/NZ222006A/xx unknown
- 1987-09-30 IL IL84040A patent/IL84040A/xx not_active IP Right Cessation
- 1987-09-30 CA CA000548208A patent/CA1320160C/en not_active Expired - Lifetime
- 1987-09-30 ZA ZA877354A patent/ZA877354B/xx unknown
- 1987-09-30 PT PT85830A patent/PT85830B/pt unknown
- 1987-09-30 IE IE262587A patent/IE59836B1/en not_active IP Right Cessation
- 1987-09-30 HU HU874416A patent/HUT45092A/hu unknown
- 1987-09-30 DK DK198705136A patent/DK172801B1/da not_active IP Right Cessation
- 1987-09-30 FI FI874273A patent/FI92716C/sv not_active IP Right Cessation
- 1987-09-30 AU AU79217/87A patent/AU616158B2/en not_active Expired
- 1987-09-30 KR KR87010890A patent/KR960009724B1/ko not_active IP Right Cessation
- 1987-09-30 JP JP62247752A patent/JP2622260B2/ja not_active Expired - Lifetime
- 1987-10-01 PH PH35871A patent/PH30662A/en unknown
-
1993
- 1993-01-21 GR GR930400097T patent/GR3006846T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5202234A (en) | Myocardial infarction immunoassay | |
| US4935343A (en) | Monoclonal antibodies for interleukin-1β | |
| MOLINARO et al. | MONOCLONAL DINITROPHENYL-SPECIFIC MURINE IgE ANTIBODY: PREPARATION, ISOLATION, AND CHARACTERIZATION1 | |
| US4921790A (en) | Tumor specific assay for CA125 ovarian cancer antigen | |
| US5382515A (en) | Creative kinase-MB immunoassay for myocardial infarction and reagents | |
| EP0119736A2 (en) | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same | |
| US4565687A (en) | Monoclonal antibodies specific for the unbound β subunit of human chorionic gonadotropin | |
| US5382522A (en) | Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents | |
| EP0580859A1 (en) | Anti-eda monoclonal antibody | |
| FI92716B (sv) | Nya monoklonala antikroppar för IFN-omega, deras framställningsförfaranden och deras användning för rening och påvisning av IFN-omega | |
| CA1338324C (en) | Monoclonal antibody for the selective immunological determination of intact procollagen peptide (type iii) and procollagen (type iii) in body fluids | |
| NO304237B1 (no) | Antistoff samt immunogent peptid egnet til immunodiagnostisk bestemmelse av revmatoid artritt | |
| WO1990006515A1 (en) | Anti-idiotopic immunometric assay | |
| KR100375564B1 (ko) | N-펩티드의샌드위치면역학적측정법 | |
| US5679583A (en) | Monoclonal antibodies for the selective immunological determination of intact procollagen peptide (type III) and procollagen (type III) in body fluids | |
| JPH07110879B2 (ja) | モノクロナール抗体 | |
| US4767710A (en) | Cell lines for the production of monoclonal antibodies to human glycophorin A | |
| KR100426029B1 (ko) | 동종 및 이종 단백질에 대한 항체, 그 항체를 이용한 진단 및 치료방법 및 그 항체의 측정방법 | |
| JPH0667319B2 (ja) | Ａｎｐのｃ端側を認識するモノクローナル抗体 | |
| JPH0534353A (ja) | ヒト９２ｋＤａゼラチナーゼの免疫学的定量法 | |
| EP0193935B1 (en) | Method for determining human prolyl 4-hydroxylase by immunoassay | |
| JPH0677017B2 (ja) | ヒト▲ｉｖ▼型コラーゲンのサンドイツチ酵素免疫学的定量法 | |
| CA2047298A1 (en) | Myocardial infarction immunoassay | |
| JP2520249B2 (ja) | ヒトプロリルヒドロキシラ−ゼの免疫学的測定法による定量法 | |
| YUE-QI et al. | Generation of monoclonal antibodies to bovine follicle-stimulating hormone and application in an enzyme immunoassay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
|
| MA | Patent expired |